CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib
DOI 10.1055/s-0033-1352702
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Stein, M Jeffers, E van Cutsem, AF Sobrero, S Siena, A Falcone, M Ychou, Y Humblet, O Bouche, L Mineur, C Barone, A Adenis, J Tabernero, T Yoshino, HJ Lenz, RM Goldberg, D Laurent, A Wagner, A Grothey
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: In the CORRECT Ph3 trial, regorafenib demonstrated significant improvement in OS and PFS vs. placebo in subjects with metastatic colorectal cancer (mCRC) who had progressed on standard therapies. An exploratory biomarker substudy was conducted on samples collected from subjects enrolled in CORRECT. Methods: DNA was isolated from archival tumor tissue and fresh baseline plasma samples that were available from 2…
Zitieren
Zitierempfehlung
A Stein, M Jeffers, E van Cutsem, AF Sobrero, S Siena, A Falcone, M Ychou, Y Humblet, O Bouche, L Mineur, C Barone, A Adenis, J Tabernero, T Yoshino, HJ Lenz, RM Goldberg, D Laurent, A Wagner, A Grothey (2013) Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352702
Mit CareLit weiterarbeiten